⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359241 | 1.00 | — | — | |
| SCHEMBL4891353 | 1.00 | — | — | |
| SCHEMBL31765 | 0.62 | — | — | |
| SCHEMBL14174692 | 0.62 | — | — | |
| SCHEMBL8499110 | 0.62 | — | — | |
| SCHEMBL1067731 | 0.62 | — | — | |
| SCHEMBL3960206 | 0.59 | — | — | |
| SCHEMBL18520975 | 0.59 | — | — | |
| SCHEMBL16327144 | 0.59 | — | — | |
| SCHEMBL9410899 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| EP-3833348-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3154989-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3131896-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-8142911-B2 | Organic compound, benzoxazole derivative, and light-emitting element, light-emitting device, and electronic device using the benzoxazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-2279757-A2 | Compounds for targeting endothelial cells | Bracco Suisse SA (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-20100256082-A1 | Metallo-hydrolase inhibitors using metal binding moietes in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7754863-B2 | Metal complex compounds for the optical recording, storage and playback of information; satisfactory sensitivity and recording properties, especially at high recording speeds | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090284142-A1 | Organic Compound, Benzoxazole Derivative, and Light-Emitting Element, light-Emitting Device, and Electronic Device Using the Benzoxazole Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-11-19 | — | — | US | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070248782-A1 | High-Capacity Optical Storage Media | CIBA SPECIALTY CHEMICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2007041365-A2 | 3-CYCLYL-2- (4-SULFAMO YL-PHENYL) -N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041366-A1 | SULFONAMIDE DERIVATIVES AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007025089-A2 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICAL, INC. (US) | 2007-03-01 | — | — | WO | disclosed |